Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

CIMPAT N

K-Number: K972485 · 1997-09-08

Decision Date1997-09-08
Product CodeEMA
Advisory CommitteeDE
DecisionSubstantially Equivalent

Device Summary

CIMPAT N is the device name listed in this FDA 510(k) record. The listed applicant is Arent, Fox, Kintner, Plotkin & Kahn. It received FDA 510(k) clearance on 1997-09-08 under 510(k) number K972485. The device is classified under product code EMA. It was reviewed by the DE advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the CIMPAT N?

CIMPAT N is a medical device that received FDA 510(k) clearance on 1997-09-08. The listed applicant is Arent, Fox, Kintner, Plotkin & Kahn. The 510(k) number is K972485.

When did CIMPAT N receive FDA 510(k) clearance?

CIMPAT N received FDA 510(k) clearance on 1997-09-08, under 510(k) number K972485.

Who is the listed applicant for CIMPAT N?

The FDA 510(k) record lists Arent, Fox, Kintner, Plotkin & Kahn as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for CIMPAT N?

The FDA product code for CIMPAT N is EMA.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Related Devices (Code: EMA)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑